Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic diseases. Its lead asset, ecnoglutide (XW003), is currently in the NDA stage in China. Leveraging proprietary platforms for oral peptide and long-acting protein therapeutics, Sciwind has built a diverse pipeline targeting GLP-1 and synergistic mechanisms, offering both injectable and oral treatment options for metabolic pateints worldwide.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 400 Fucheng Road, #2-9f, Hangzhou,zhejiang 310018,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sciwindbio.com
- HQ
- Hangzhou, Zhejiang
Sciwind Biosciences Questions
Sciwind Biosciences's website is http://www.sciwindbio.com
Sciwind Biosciences's LinkedIn profile is https://www.linkedin.com/company/sciwind-biosciences
Sciwind Biosciences has
8 employees.
View email and phone details for 8
employees at Sciwind Biosciences.
Sciwind Biosciences's industry is
Biotechnology Research
Sciwind Biosciences's top competitors are
Medilink Therapeutics,
Starna Therapeutics,
Mediar Therapeutics,
Kailera Therapeutics,
Lyfe Capital,
Tenvie Therapeutics,
Aiolos Bio,
Verdiva Bio,
Viking Therapeutics, Inc.,
Terns Pharmaceuticals.
Sciwind Biosciences's categories are Biotechnology Research
Sciwind Biosciences's founding year is 2017
